MedTrace Logo

A Post-marketing Observational Study of Cell Therapy for Chronic Wounds

NCT01038986 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2013-01-31

No results posted yet for this study

Summary

A post-marketing multi-center observational study to provide data describing the safety and effectiveness of CUREXCELL™ as it is applied in a real-life setting for treatment in patients with chronic and/or refractory wounds.

Conditions

  • Wounds

Interventions

BIOLOGICAL

CureXcell

The CureXcell™ dosage form consists of an aseptically-processed activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.

Sponsors & Collaborators

  • Macrocure Ltd.

    lead INDUSTRY

Principal Investigators

  • Itzchak Zivner, MD · Sheba Medical Center

  • Eli Peled, M.D. · Rambam Health Care Campus, Israel

  • Dean David Ad-El, M.D. · Rabin-Schnider Medical Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-08-31
Completion
2012-10-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01038986 on ClinicalTrials.gov